Study population
The current study investigated the dietary acid load in association with the risk of CVD in the framework of the prospective TLGS [18]. The longitudinal population-based TLGS aims to alleviate the non-communicable diseases (NCDs) and NCD-related risk factors and promote a healthier lifestyle within the community. First phase of the TLGS was initiated in 1999 and recruited 15005 participants from residents of district 13 of Tehran (≥ 3 years of age) by multistage cluster random sampling [19]. To assess any possible changes to the NCD risk factors, the collected data and required measurements were taken triennially.
This study is based on the data of phase III to VI of the TLGS (2006- 2008 to 2014). Within this period, the demographic, anthropometric, biochemical, and dietary examinations were completed by 12523 individuals and the dietary assessments were taken from a random sample of 4920 participants. The randomization reduced the cost, complexity, and the time required for data collection. With a response rate of 30%, the dietary data was obtained for 3678 individuals. Participants were subsequently excluded if they were out of the predefined age limit (below 19 and above 70 years old; n= 626), had suspected report of energy consumption (below 800 and above 4200 kcal/day; n= 579), were diagnosed with CVD history at baseline (myocardial infarction, stroke, angina, coronary revascularization; n= 90), and had any missing data or lost to follow-up (n= 14). Finally, a total of 2369 adults (1030 men and 1339 women) were selected for the analysis. Participants with full report of the food frequency questionnaire (FFQ) shared resembling baseline features with the general population of the third phase of TLGS. In this regard, the FFQs were completed by 76.7% of the participants, comparing to 82.3% in the total population of the third phase. Also, the age distribution for participants with and without CVD outcomes were 58.4 ± 9.7 and 37.4 ± 12.8 years (P = 0.001), respectively. Figure 1 illustrates the stages involved in participants’ selection in details.
The protocol of the current study was approved by the ethics research council of the Research Institute for Endocrine Science, Shahid Beheshti University of Medical Science, Tehran, and all methods complied with this council’s guidelines and regulations.
Demographic and anthropometric measurements
A group of trained interviewers have collected the demographic information using standardized questionnaires. Variable measurements of the TLGS are described in details elsewhere [20]. The frequency and duration of light to very intense physical activity (expressed as metabolic equivalent hours per week; MET-h/wk) was assessed by a Modifiable Activity Questionnaire (MAQ) [21]. The anthropometric measurements including weight and height were taken using digital scales and ‘drop-down’ tape meters, respectively, and the waist circumference was obtained in the midway between the lower border of the ribs and the iliac crest. Consequently, body mass index (BMI) was calculated by the division of weight (kg) by height the squared (m2). Systolic (SBP) and diastolic blood pressure (DBP) were measured twice on the right arm via a standard mercury sphygmomanometer. The mean of the two measurements were considered as the final blood pressure.
Biochemical measurements
Baseline and follow-up blood samples were taken from all participants following a 12-14 hour fasting. Enzymatic colorimetric was used to measure the triglyceride (TG) level and the fasting serum glucose (FSG), using phosphate oxidase and glucose oxidase, respectively. High-density lipoprotein cholesterol (HDL-C) level was obtained following the precipitation of the apolipoprotein B containing lipoproteins with phosphotungstic acid. The Pars Azmoon kits (Pars Azmoon Inc., Tehran, Iran) and a Selectra 2 auto-analyzer (Vital Scientific, Spankeren, Netherlands) were used to perform the analysis.
Dietary assessment
Demographic, anthropometric, biochemical, and dietary data were obtained at baseline (2006- 2008). The habitual dietary intake of individuals within the past year was assessed by an expert interviewer, via a validated 168-item semi-quantitative FFQ [22]. The reliability and validity of the questionnaire were previously evaluated in a random sample and proven to be reasonable. The food and beverage consumption frequency of the participants were recorded on a daily, weekly, or monthly basis [20] and the household-measured portion sizes were then converted to grams. To analyze the energy and nutritional content of the raw food items, the US Department of Agriculture Food Composition Table (USDA FCT) was used. Since the Iranian Food Composition Table lacks the necessary data on the dietary composition of the food items, it was merely used for the traditional food items not listed within the USDA FCT [23] .
Dietary acid load calculation
The dietary PRAL is a validated proxy for renal net acid excretion that explains the contribution of a food or a diet to the NEAP [1,24]. Also, the dietary NEAP score is defined as the total nonvolatile acid load that results from endogenous acid production and gastrointestinal absorption [4]. A diet with acidifying potentials has superior PRAL and NEAP scores [16, 17]. The population distribution across the tertiles of dietary PRAL are illustrated in table 1. In this regard, 792 participants had PRAL lower than -15.3 mEq/day, 798 individuals were designated with PRAL between -15.3 to -1.14 mEq/day and the remaining acquired higher PRAL than -1.15 mEq/day. The dietary PRAL was calculated based on the protein, phosphorus, potassium, calcium, and magnesium intake values [7,24], whereas the NEAP score calculation relied merely on the consumption of protein and potassium [8].
PRAL (mEq/d) = [protein (g/d) × 0.49] + [phosphorus (mg/d) × 0.037] - [potassium (mg/d) × 0.021] - [calcium (mg/d) × 0.013] - [magnesium (mg/d) × 0.026]
NEAP (mEq/d) = [{54.5 × protein (g/d)} / potassium (mEq/d)] – 10.2
Table 1
Baseline characteristics of 2369 Iranian adults aged ≥ 19 years across tertiles of PRAL: Tehran Lipid and Glucose Study (TLGS)
|
|
PRAL (mEq/d)
|
|
|
|
< -15.3 (n=792)
|
-15.3 to –1.14 (n=789)
|
>-1.15 (n=788)
|
P-value
|
Age (y)
|
40.2 ± 13.7
|
39.1 ± 13.2
|
36.3 ± 12.6
|
0.001
|
Sex (% male)
|
36.5
|
39.9
|
54.1
|
0.001
|
BMI (kg/m2)
|
27.1 ± 4.8
|
26.6 ± 4.8
|
26.1 ± 4.7
|
0.001
|
Current smoker (%)
|
9.8
|
12.3
|
14.1
|
0.044
|
Physical activity (MET-H/week)
|
37.1 ± 64.6
|
35.1 ± 51.1
|
35.7 ± 58.8
|
0.806
|
Hypertension (%)
|
37.4
|
32.9
|
29.7
|
0.306
|
Diabetes (%)
|
3.9
|
5.7
|
2.6
|
0.010
|
Data are presented as mean (± SD) for continuous variables and as percentage for categorical variables.
Hypertension (HTN): systolic blood pressure (SBP) ≥ 140 mm Hg or diastolic blood pressure (DBP) ≥ 90 mm Hg, or blood pressure-lowering medication.
Type 2 diabetes (T2DM): fasting serum glucose ≥ 126 mg/dL, or 2 h-SG≥ 200 mg/dL, or anti-diabetic medication.
|
Definition of terms
The sex-specific “general CVD” algorithms was used to compute the CVD risk score based on age, smoking and diabetic status, total cholesterol (TC), HDL-C and SBP levels, and hypertension treatment [7]. Diabetes was defined as the FSG level over 126 mg/dL, 2-h serum glucose above 200 mg/dL or administration of anti-diabetic medications [21]. Hypertension was also explained as SBP above 140 mm Hg, DBP higher or equal to 90 mm Hg, or concurrent treatment with antihypertensive medications [22].
Definition of outcomes
In the current study, participants were followed-up annually by telephone calls and the required information on the possible medical events were collected by a trained nurse or a physician. Further information were extracted from the medical records. The collected data were reviewed by an adjudication committee, which included a physician, an internist, an epidemiologist, a cardiologist, an endocrinologist, and associate external experts as needed. The final diagnosis was reported by a predefined coding protocol [25].
CVD-related data collection procedure is described in details elsewhere [20]. The CVD terminology was primarily defined as any history of definite fatal and non- fatal stroke, coronary heart disease (CHD) or definite fatal CHD, and CVD mortality (definite fatal myocardial infarction; MI)) [26]. The CHD was also explained by any cases of definite or probable MI, unstable angina pectoris, and sudden cardiac death [27].
Statistical Analysis
In this study, version 20.0 (SPSS Inc., Chicago, IL, USA) of IBM SPSS was used to perform the data analyses and p-values higher than 0.05 were statistically significant. The mean and the frequency of the baseline characteristics across tertiles of dietary PRAL were compared by univariate analysis or chi-square. The frequency of qualitative variables were measured by the chi-square test. The cofounders of the univariate analysis included the CVD incidence risk score, total dietary energy, and total dietary fat. The physical activity factor was eliminated from the final multivariable model due to the significant PE value (PE > 0.2). To compute the hazard ratios (HRs) and the 95% confidence intervals (CIs), the Cox proportional hazards regression model was performed with person-year as the underlying time metric. Two models were adjusted for the potentially cofounding variables and the CVD incidence risk hazard ratios were estimated across tertiles of PRAL and NEAP. The first model was adjusted for TC, HDL-c, hypertension treatment, type 2 diabetes, smoking, and age, and in accordance with the CVD incidence risk score and the general CVD algorithms specified for each gender [28]. The CVD incidence risk score validation was previously assessed among the Iranian population and remained as the leading predictor of CVD events [29]. For the second model, adjustments of total dietary energy and total fat intake were also applied. The Cox proportional hazard regression model used the median values of dietary PRAL, which was considered as a continuous variable in the assessment of overall HR trends across the tertile categories. The concept of time to event has described the onset of an event, or the completion time of the follow-up.